Your browser doesn't support javascript.
loading
Steroid Use for Recovery of advanced atrioVentricular block Immediately after VALvular surgery (SURVIVAL): A preliminary randomized clinical trial.
Ghodsi, Saeed; Masoudkabir, Farzad; Hosseini, Zahra; Davarpasand, Tahereh; Yavari, Negin; Mohebi, Mehrnaz; Talasaz, Azita H; Jalali, Arash; Ahmadi-Tafti, Seyed H; Bagheri, Jamshid; Hasanzadeh, Hakimeh.
Afiliação
  • Ghodsi S; Cardiac Primary Prevention Research Center, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran.
  • Masoudkabir F; Cardiac Primary Prevention Research Center, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran.
  • Hosseini Z; Department of Cardiology, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran.
  • Davarpasand T; Cardiac Primary Prevention Research Center, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran.
  • Yavari N; Department of Cardiology, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran.
  • Mohebi M; Cardiac Primary Prevention Research Center, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran.
  • Talasaz AH; Cardiac Primary Prevention Research Center, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran.
  • Jalali A; Department of Cardiology, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran.
  • Ahmadi-Tafti SH; Cardiac Primary Prevention Research Center, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran.
  • Bagheri J; Department of Cardiac Surgery, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran.
  • Hasanzadeh H; Department of Cardiac Surgery, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran.
J Cardiovasc Electrophysiol ; 33(4): 575-585, 2022 04.
Article em En | MEDLINE | ID: mdl-35066948
ABSTRACT

BACKGROUND:

Atrioventricular block (AVB) is an important complication following valvular surgery. Several factors including inflammation-mediated injury might trigger AVB.

METHODS:

Patients with advanced postoperative AVB were randomly assigned to receive either dexamethasone (0.4 mg/kg, maximum 30 mg/day) intravenously for 3 days or conservative care only. Primary endpoint was recovery rate in Day 5 since randomization. Secondary endpoints were recovery rate in Day 7 and Day 10, cumulative AVB time, permanent pacemaker (PPM) implantation rate, length of stay in critical care units, and postoperative major adverse events (MAE).

RESULTS:

We enrolled 139 subjects (48.9% male) with mean age of 59.9 years randomly allocated to intervention group (n = 69) and control group (n = 70). Dexamethasone led to higher recovery rates at Day 5 (82.6% vs. 62.9%, p = .009) and Day 7 (88.4% vs. 61.4%, p < .0001) respectively. This benefit ceased at Day 10 (83.05% vs. 78.6%, p = .547). Median cumulative AVB time was shorter in dexamethasone group compared with control group (41 h vs. 64 h, p = .044). PPM implantation rates were similar between the dexamethasone and control groups (15.9% vs. 17.1%, respectively, p = .849). Median length of stay in intensive care unit (ICU) (10 days vs. 12 days, p = .03) and MAE (17.4% vs. 25.7%, p = .133) tended to be lower with dexamethasone.

CONCLUSION:

Dexamethasone may serve as a safe and effective medication to help hasten recovery of advanced AVB after valvular surgery.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Marca-Passo Artificial / Bloqueio Atrioventricular Tipo de estudo: Clinical_trials / Diagnostic_studies / Etiology_studies Limite: Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Marca-Passo Artificial / Bloqueio Atrioventricular Tipo de estudo: Clinical_trials / Diagnostic_studies / Etiology_studies Limite: Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2022 Tipo de documento: Article